I have no idea about that conclusion. I wouldn't have thought that the need to raise cash in the near term was necessarily tied to the success or failure of P.
FWIW.... R&D expenses were ~$700K more than the same quarter of last year. In part explained by: "Research and development expenses for proprietary programs increased during the three months ended March 31, 2016 primarily due to more spending on our Brilacidin program." $3m was spent on R&D in the last three months while $4m was spent in the previous six.
Study was blind and only finished on 5/2 or something like that...stop saying your opinion as fact...they did not have any clue of the results until after all that money was brought in. The fact it wasn't HIGHER amounts should actually tell you how confident they are...